Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel

Background. The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D. Methods. Treatment consisted of D 30 mg/m(2) i.v. for four consecutive weekly administ...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Francini, Filippo, Pascucci, Alessandra, Francini, Edoardo, Bargagli, Gianluca, Conca, Raffaele, Licchetta, Antonella, Roviello, Giandomenico, Martellucci, Ignazio, Chiriacò, Giorgio, Miano, Salvatora Tindara, Marzocca, Giuseppe, Manganelli, Antonio, Ponchietti, Roberto, Savelli, Vinno, Petrioli, Roberto
פורמט: Artigo
שפה:Inglês
יצא לאור: Hindawi Publishing Corporation 2011
נושאים:
Clinical Study
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3200276/
https://ncbi.nlm.nih.gov/pubmed/22096653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2011/258689
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים